Healthcare > Pharmaceuticals & Biotechnology
•2434 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2434)
| Company | Market Cap | Price |
|---|---|---|
|
SCNX
Scienture Holdings, Inc.
Arbli (SCN-102) is a cardiovascular drug (losartan liquid formulation) indicated for hypertension and related conditions.
|
$8.53M |
$0.56
+6.05%
|
|
BCDA
BioCardia, Inc.
CardiAMP and CardiALLO are BioCardia's direct cell-therapy programs (autologous and allogeneic) targeted for cardiovascular disease.
|
$8.41M |
$1.46
+0.34%
|
|
PULM
Pulmatrix, Inc.
Pulmatrix's core offering is the iSPERSE dry powder drug delivery platform, a direct product category.
|
$8.40M |
$2.25
-2.39%
|
|
AIMD
Ainos, Inc.
VELDONA human therapeutic programs target rare diseases, aligning with Biotech - Rare Diseases.
|
$8.34M |
$1.80
+0.56%
|
|
TSBX
Turnstone Biologics Corp.
Company's core business is oncology-focused biotechnology, including immunotherapy approaches (TIL-based strategies) in solid tumors.
|
$8.21M |
$0.35
|
|
MBIO
Mustang Bio, Inc.
Develops cell therapy products, primarily CAR T therapies (cell-based immunotherapies).
|
$8.18M |
$1.18
+3.98%
|
|
GELS
Gelteq Limited Ordinary Shares
Gelteq's core offering is a gel-based drug delivery platform used across nutraceuticals, pet care, sports, OTC, and pharmaceutical products.
|
$8.07M |
$0.80
-7.02%
|
|
ENTO
Entero Therapeutics, Inc.
Adrulipase is a recombinant lipase enzyme produced as a therapeutic for exocrine pancreatic insufficiency, fitting Recombinant Proteins & Enzymes.
|
$7.83M |
$2.96
-36.48%
|
|
BMRA
Biomerica, Inc.
Offers Contract Manufacturing services with notable growth, i.e., contract manufacturing revenue stream.
|
$7.83M |
$2.85
+2.52%
|
|
EVAX
Evaxion Biotech A/S
Evaxion develops vaccines, including EVX-01 for cancer and multiple infectious-disease vaccine programs.
|
$7.56M |
$5.12
-5.01%
|
|
KPRX
Kiora Pharmaceuticals, Inc.
Company's pipeline focuses on ophthalmic therapeutics (KIO-301, KIO-104) targeting retinal degenerative diseases and retinal inflammation, i.e., Ophthalmic Drugs.
|
$7.52M |
$2.19
|
|
ALZN
Alzamend Neuro, Inc.
Company's pipeline includes Alzheimer's disease therapeutics (ALZN002) and a focused strategy on Alzheimer's treatment.
|
$7.35M |
$2.33
-0.43%
|
|
KTTA
Pasithea Therapeutics Corp.
Pasithea's lead candidate PAS-4.00 is a MEK inhibitor targeting MAPK pathway-driven tumors, aligning with oncology-focused biotech.
|
$7.22M |
$0.92
-5.15%
|
|
BGLC
BioNexus Gene Lab Corp.
Chemrex pivot to biotech-focused CDMO activities positions it as a Contract Manufacturing Organization.
|
$7.20M |
$3.85
-3.87%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL is based on RNA interference (siRNA), making RNAi therapeutics a core product/framework.
|
$6.93M |
$1.18
-2.89%
|
|
PCSA
Processa Pharmaceuticals, Inc.
Processa is a oncology-focused biotech developing Next Generation Cancer therapies (NGCs), placing it squarely in Biotech - Oncology.
|
$6.92M |
$3.41
-0.73%
|
|
ICU
SeaStar Medical Holding Corporation
QUELIMMUNE represents an immunology therapeutic, aligning with Immunology Therapeutics.
|
$6.87M |
$2.48
+0.81%
|
|
PPCB
Propanc Biopharma, Inc.
Propanc Biopharma is a development-stage biotechnology company focusing on oncology therapies, making PRP its core candidate.
|
$6.55M |
$0.48
-6.77%
|
|
ADIL
Adial Pharmaceuticals, Inc.
Lead AUD program is a neuropsychiatric CNS therapeutic, aligning with Neuropsychiatric Drug Development.
|
$6.45M |
$0.28
-3.65%
|
|
SBFM
Sunshine Biopharma, Inc.
SBFM's Nora Pharma operates a growing Canadian generic prescription drug business.
|
$6.42M |
$1.35
-4.26%
|
|
DQWS
DSwiss, Inc.
DQWS provides turnkey OEM/ODM contract manufacturing services for health care, beauty, and nutraceutical products.
|
$6.41M |
$0.04
|
|
SNGX
Soligenix, Inc.
HyBryte CTCL and related oncology assets position Soligenix in Biotech - Oncology.
|
$6.26M |
$1.43
-2.40%
|
|
ADXN
Addex Therapeutics Ltd
Addex's core product category is oral small-molecule therapeutics (allosteric modulators including GABAB PAMs and mGluR modulators).
|
$6.25M |
$8.00
+3.63%
|
|
RNAZ
TransCode Therapeutics, Inc.
TransCode Therapeutics operates in biotech oncology, developing cancer therapeutics.
|
$6.23M |
$7.76
+3.88%
|
|
HIGR
Hi-Great Group Holding Company
KRAS gene license places HIGR in Biotech - Oncology, an oncology-focused biotech asset.
|
$6.21M |
$0.06
|
|
SNOA
Sonoma Pharmaceuticals, Inc.
Eye care products, aligning with ophthalmic drug offerings.
|
$6.20M |
$3.78
+0.27%
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Core focus on autoimmune immunology therapeutics with lead asset hCDR1.
|
$6.18M |
$0.63
-4.58%
|
|
CELZ
Creative Medical Technology Holdings, Inc.
CELZ develops autologous/allogeneic cell therapies (ImmCelz and AlloStem), a core cell therapy business.
|
$6.17M |
$2.33
-2.30%
|
|
IDXG
Interpace Biosciences, Inc.
Interpace focuses on oncology-focused molecular diagnostics and cancer risk biomarker testing, including thyroid-related cancer risk assessment.
|
$6.14M |
$1.07
|
|
IBO
Impact BioMedical Inc.
Linebacker is an oncology-focused platform of electrophilically enhanced polyphenol compounds licensed for development and commercialization.
|
$6.12M |
$0.49
-5.76%
|
|
BIXT
Bioxytran, Inc.
ProLectin-M is an oral antiviral candidate; fits the Oral Small Molecule Therapeutics category as a major product line.
|
$6.07M |
$0.07
|
|
MBRX
Moleculin Biotech, Inc.
Moleculin Biotech's lead asset Annamycin is a cancer drug candidate, placing the company squarely in the Biotech - Oncology category.
|
$6.03M |
$5.04
+0.80%
|
|
CYCN
Cyclerion Therapeutics, Inc.
Cyclerion is centered on neuropsychiatric drug development, specifically an individualized therapy for Treatment Resistant Depression (TRD).
|
$6.01M |
$1.83
+1.94%
|
|
APM
Aptorum Group Limited
Aptorum plans near-term revenue from biopharma services via the DiamiR merger, aligning with contract research/Development outsourcing.
|
$5.95M |
$1.07
+1.42%
|
|
LYRA
Lyra Therapeutics, Inc.
XTreo drug-delivery platform is Lyra's core product, enabling six months of localized drug therapy via in-office implant (LYR-210).
|
$5.94M |
$3.60
-0.42%
|
Showing page 23 of 25 (2434 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
